TY - JOUR
T1 - The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders
AU - Sindher, Sayantani B.
AU - Barshow, Suzanne
AU - Tirumalasetty, Jyothi
AU - Arasi, Stefania
AU - Atkins, Dan
AU - Bauer, Maureen
AU - Bégin, Philippe
AU - Collins, Margaret H.
AU - Deschildre, Antoine
AU - Doyle, Alfred D.
AU - Fiocchi, Alessandro
AU - Furuta, Glenn T.
AU - Garcia-Lloret, Maria
AU - Mennini, Maurizio
AU - Rothenberg, Marc E.
AU - Spergel, Jonathan M.
AU - Wang, Julie
AU - Wood, Robert A.
AU - Wright, Benjamin L.
AU - Zuberbier, Torsten
AU - Chin, Andrew R.
AU - Long, Andrew
AU - Nadeau, Kari C.
AU - Chinthrajah, R. Sharon
N1 - Publisher Copyright:
© 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023/3
Y1 - 2023/3
N2 - Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.
AB - Continuing insight into the molecular mechanisms of atopic disorders has enabled the development of biologics to precisely target these diseases. Food allergy (FA) and eosinophilic gastrointestinal disorders (EGIDs) are driven by similar inflammatory molecular mechanisms and exist along the same atopic disease spectrum. Therefore, many of the same biologics are being investigated to target key drivers of mechanisms shared across the disease states. The enormous potential of biologics for the treatment of FA and EGIDs is highlighted by the significant increases in the number of ongoing clinical trials (more than 30) evaluating their use in these disease states, as well as by the recent US Food and Drug Administration approval of dupilumab for the treatment of eosinophilic esophagitis. Here we discuss past and current research into the use of biologics in FA and EGIDs and their potential role in improving treatment options in the future, with the need to have biologics widely clinically available.
KW - Food allergy
KW - biologics
KW - eosinophilic colitis
KW - eosinophilic enteritis
KW - eosinophilic esophagitis
KW - eosinophilic gastritis
KW - eosinophilic gastrointestinal disorders
KW - oral immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85149063640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149063640&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2023.01.007
DO - 10.1016/j.jaci.2023.01.007
M3 - Review article
C2 - 36872039
AN - SCOPUS:85149063640
SN - 0091-6749
VL - 151
SP - 595
EP - 606
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -